Journal
CANCER BIOLOGY & THERAPY
Volume 2, Issue 5, Pages 544-551Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.2.5.454
Keywords
leukemia; Bcr/Abl; histone deacetylase inhibitors; apoptosis; JNK
Categories
Funding
- NCI NIH HHS [CA93738, CA63753] Funding Source: Medline
Ask authors/readers for more resources
Signal transduction events regulating induction of apoptosis by the histone deacetylase inhibitors (HDIs) sodium butyrate (SB) and SAHA have been examined in Bcr/Abl(+), human leukemia cells (K562, LAMA 84). Exposure of K562 cells to greater than or equal to 3.0 mM SB or 3.0 muM SAHA for 24-48 hr resulted in a marked induction of mitchondrial damage (e.g., cytochrome c release) and apoptosis, events associated with downregulation of Bcr/Abl and Raf-1, induction of p21(CIP1), inactivation of MEK1/2, ERK1/2, and p70(S6K), and a dramatic increase in JNK activation. HDI-mediated apoptosis was attenuated by pharmacologic JNK inhibitors and enhanced by the MEK1//2 inhibitor U0126 as well as by the JNK activator anisomycin. Interestingly, HDI-induced JNK activation was potentiated by pharmacologic MEK inhibition. Furthermore, HDI lethality was significantly diminished in cells ectopically expressing constitutively active MEK1, confirming a functional role for MEK/ERK inactivation in HDI-mediated apoptosis. Similar events were observed in Bcr/Abl(+) LAMA 84 cells. Lastly, the free radical scavenger L-N-acetylcysteine (LNAC) attenuated HDI-mediated ROS generation, JNK activation, and apoptosis. Together, these findings support a model in which induction of apoptosis in Bcr/Abl+ cells by HDIs involves coordinate inactivation of the cytoprotective Raf/MEK/ERK pathway in conjunction with the ROS-dependent activation of JNK.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available